BPC-157, TB-500 & CJC-1295: The Clinical Evidence
BPC-157 and TB-500 have almost no robust human clinical evidence, and CJC-1295 has only early human data that tracks hormone changes rather than patient outcomes. None of the three has the large, blinded, randomized record that would let a careful clinician call it established treatment.
This article is for general information only and is not medical advice. Always read the manufacturer's leaflet and speak to a qualified healthcare professional before using any medicine.
Keep reading
Topical steroid withdrawal (TSW), also called red skin syndrome or topical corticosteroid withdrawal, is the reaction that can follow stopping topical corticosteroids after prolonged use - typicall...
Across the SURMOUNT phase 3 program, tirzepatide produced mean weight loss of up to 20.9% at 72 weeks in adults without diabetes (SURMOUNT-1) and up to 15.7% in adults with type 2 diabetes (SURMOUN...
Semaglutide generally produces more weight loss and asks less of you day to day — once weekly instead of once daily. In the head-to-head STEP 8 trial, semaglutide 2.4 mg weekly produced 15.8% mean ...